Skip to Content

Apremilast

In the US, Apremilast (apremilast systemic) is a member of the drug class antirheumatics and is used to treat Plaque Psoriasis and Psoriatic Arthritis.

US matches:

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L04AA32

CAS registry number (Chemical Abstracts Service)

0608141-41-9

Chemical Formula

C22-H24-N2-O7-S

Molecular Weight

460

Therapeutic Categories

Antiasthmatic agent

Immunosuppressant

Antipsoriatic

Tumor necrosis factor alpha (TNF-α) inhibitor

Chemical Name

N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methanesulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (WHO)

Foreign Names

  • Apremilastum (Latin)
  • Apremilast (German)
  • Aprémilast (French)
  • Apremilast (Spanish)

Generic Names

  • Apremilast (OS: USAN)
  • UNII-UP7QBP99PN (IS)

Brand Names

  • Otezla
    Celgene, Canada; Celgene, Switzerland; Celgene, Germany; Celgene, United Kingdom; Celgene, Ireland; Celgene, United States; Celgene Europe, Slovenia

International Drug Name Search

Glossary

TermDefinition
ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Hide